NBIX240816C145000
- 9.42
- +1.92+25.60%
Neurocrine Biosciences Newsroom
These 4 Measures Indicate That Neurocrine Biosciences (NASDAQ:NBIX) Is Using Debt Safely
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you
S&P 500 Futures Climb In Premarket Trading; Neurocrine Biosciences, Equitable Holdings Lead
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Neurocrine Biosciences Inc. (NBIX) was up 8.8% in
Express News | Neurocrine Biosciences Inc : BMO Raises Target Price to $142 From $138
Neurocrine Biosciences Rolls Out Ingrezza Sprinkle Capsules to Treat Tardive Dyskinesia, Chorea With Huntington's Disease
Neurocrine Biosciences (NBIX) said Thursday it has launched a new sprinkle formulation of Ingrezza capsules to treat adults with tardive dyskinesia and chorea associated with Huntington's disease, a
Express News | Neurocrine Biosciences Launches INGREZZA SPRINKLE Capsules
Express News | Neurocrine Biosciences Launches Ingrezza® Sprinkle (Valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
Neurocrine Biosciences Launches INGREZZA SPRINKLE (Valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
Most people living with chorea associated with Huntington's disease will experience swallowing issues," said Katie Jackson, President, Help 4 HD International.
Neurocrine Is Maintained at Overweight by Morgan Stanley
Neurocrine Is Maintained at Overweight by Morgan
Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $170
Morgan Stanley analyst Jeffrey Hung maintains $Neurocrine Biosciences(NBIX.US)$ with a buy rating, and adjusts the target price from $160 to $170.According to TipRanks data, the analyst has a
Morgan Stanley Keeps Their Buy Rating on Neurocrine (NBIX)
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Thursday, August 1SAN DIEGO, July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second
S&P 500 Futures Fall In Premarket Trading; Delta Air Lines, Viking Therapeutics Lag
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Range Resources Corp. (RRC) was up 3.3% in pre-
Top Medical Stocks to Buy for Growth & Performance
The higher the broader indexes go, the more conscious investors will be of investments that may offer defensive safety.
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
Analysts' ratings for Neurocrine Biosciences (NASDAQ:NBIX) over the last quarter vary from bullish to bearish, as provided by 16 analysts.The table below offers a condensed view of their recent
Neurocrine Is Maintained at Overweight by JP Morgan
Neurocrine Is Maintained at Overweight by JP
Express News | JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $173
Neurocrine Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 19.77% JP Morgan $169 → $173 Maintains Overweight 06/12/2024 10.77% Morgan Stanley $160 → $160
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $173
J.P. Morgan analyst Anupam Rama maintains $Neurocrine Biosciences(NBIX.US)$ with a buy rating, and adjusts the target price from $169 to $173.According to TipRanks data, the analyst has a success
Buy Rating Affirmed for Neurocrine Biosciences on Strong Drug Pipeline and Promising Schizophrenia Treatment Prospects